SFRP2 and dysplasia: In a study including 35 patients with cancer, 78 with dysplasia, and 343 without neoplasia undergoing surveillance for UC-CRC across six medical centers, a multiplex methylation panel including five markers (SFRP2, SFRP4, WIF1, APC1A, APC2) was accurate in detecting pre-cancerous and invasive neoplasia (AUC = 0.83; 95% CI: 0.79, 0.88), and dysplasia (AUC = 0.88; (0.84, 0.91).